ALNYLAM PHARMACEUTICALS INC (ALNY)
US02043Q1076 - Common Stock
We assign a fundamental rating of 3 out of 10 to ALNY. ALNY was compared to 609 industry peers in the Biotechnology industry. ALNY may be in some trouble as it scores bad on both profitability and health. ALNY is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
ALNY had negative earnings in the past year.
ALNY had a positive operating cash flow in the past year.
ALNY had negative earnings in each of the past 5 years.
In the past 5 years ALNY always reported negative operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of -13.28%, ALNY belongs to the best of the industry, outperforming 87.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.28% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-26.83%
ROA(5y)-33.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 84.00%, ALNY belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
ALNY's Gross Margin has declined in the last couple of years.
ALNY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.86%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ALNY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALNY has more shares outstanding
Compared to 5 years ago, ALNY has more shares outstanding
Compared to 1 year ago, ALNY has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.47, we must say that ALNY is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.47, ALNY is in the better half of the industry, outperforming 67.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.47 |
ROIC/WACCN/A
WACC11.09%
2.3 Liquidity
ALNY has a Current Ratio of 3.14. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
ALNY's Current ratio of 3.14 is on the low side compared to the rest of the industry. ALNY is outperformed by 67.17% of its industry peers.
A Quick Ratio of 3.04 indicates that ALNY has no problem at all paying its short term obligations.
The Quick ratio of ALNY (3.04) is worse than 67.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.04 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 54.70% over the past year.
ALNY shows a strong growth in Revenue. In the last year, the Revenue has grown by 79.37%.
Measured over the past years, ALNY shows a very strong growth in Revenue. The Revenue has been growing by 63.09% on average per year.
EPS 1Y (TTM)54.7%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q142.75%
Revenue 1Y (TTM)79.37%
Revenue growth 3Y67.74%
Revenue growth 5Y63.09%
Revenue growth Q2Q183.96%
3.2 Future
Based on estimates for the next years, ALNY will show a very strong growth in Earnings Per Share. The EPS will grow by 25.37% on average per year.
The Revenue is expected to grow by 32.47% on average over the next years. This is a very strong growth
EPS Next Y58.07%
EPS Next 2Y22.44%
EPS Next 3Y23.15%
EPS Next 5Y25.37%
Revenue Next Year79.79%
Revenue Next 2Y32.67%
Revenue Next 3Y33.44%
Revenue Next 5Y32.47%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ALNY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALNY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ALNY's earnings are expected to grow with 23.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.44%
EPS Next 3Y23.15%
5. Dividend
5.1 Amount
No dividends for ALNY!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALNYLAM PHARMACEUTICALS INC
NASDAQ:ALNY (12/8/2023, 7:00:01 PM)
After market: 170.04 0 (0%)170.04
-7.22 (-4.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap21.34B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.28% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 84% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.04 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)54.7%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y58.07%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)79.37%
Revenue growth 3Y67.74%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y